Integrated Research faces renewal and credit risks despite A$51.7 million cash

Revenue Decline and Credit Losses Crush FY26 Profit

Integrated Research Limited (ASX:IRI) finished FY26 with the uncomfortable combination of falling sales, heavier investment and a large receivables hit. Statutory revenue dropped 16% to A$57.6 million, while profit after tax fell 91% to A$1.2 million and statutory EBITDA swung to a A$2.1 million loss.

The annual report attributes the revenue decline to a weaker renewals book, lower new business and deals deferred into FY27 as enterprise customers took longer to clear compliance and procurement hurdles. Expenses rose 7% to A$58.8 million, including a A$5.0 million expected credit-loss provision that was principally tied to one client contract. The provision was a particularly sharp drag on a business that otherwise generated a net operating cash inflow of A$12.6 million.

The figures confirm the deterioration outlined in the FY26 profit slide, which reported the same 91% fall in net profit and highlighted the tension between weaker renewals and continued AI investment. Product performance was uneven: Collaborate revenue fell 27% to A$24.0 million and Infrastructure declined 19% to A$14.7 million, while Transact rose 18% to A$15.6 million on strong renewals and early contract renewals by clients.

Cash Strength Preserves Investment Capacity

IR’s balance sheet provides a meaningful buffer while the business attempts to reset its growth profile. Cash increased 27% to A$51.7 million at 30 June, with no borrowings, despite the payment of A$3.5 million in dividends during the year. The improvement in cash also reflected lower trade receivables and stronger cash conversion, although the new credit-loss provision means the quality and recoverability of customer balances remain important issues.

Management increased product and technology spending by 29% to A$17.4 million, equivalent to 30% of revenue, and expensed all of it rather than capitalising development costs. The spending supported the launch of Iris, an AI interface for the Prognosis platform, IR Labs’ standalone Agentic SQA product, and Prognosis Elevate, a cloud-hosted service offering. IR also completed implementation of its High Value Payments product with a top-ten US bank.

FY27 Commercialisation Must Follow Product Launches

The report is clear that these products have not yet become a material revenue stream. First customers have been activated across several offerings, but adoption, utilisation and conversion into recurring revenue remain at an early stage. The company says FY27 will focus on commercialisation, customer engagement, renewals and sales execution rather than product development alone.

That creates a demanding test. The company’s constant-currency net revenue retention rate for Collaborate remained at 83%, while shorter contract terms and lengthening enterprise sales cycles put pressure on visibility. Total contract value fell to A$54.3 million from A$67.3 million, and management identifies customer adoption, competitive AI disruption, retention and delayed procurement as key risks to the next phase.

The Board declared fully franked dividends of 3 cents per share and 2 cents per share, ordinary and special respectively, for a combined 5 cents. The payout is supported by the cash balance, but the central investment question is now less about IR’s ability to fund innovation than whether that innovation can produce enough new business to offset the renewals pressure.